ArticleInflammopharmacology2020

Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.

Elena Silvestri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.